Phase 2 Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type Clinical Trials
2 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–2 of 2 trials
Recruiting
Phase 2
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+12 more
National Cancer Institute (NCI)120 enrolled82 locationsNCT06649812
Recruiting
Phase 2
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Recurrent Grade 3b Follicular LymphomaRefractory Grade 3b Follicular LymphomaRecurrent Transformed Non-Hodgkin Lymphoma+28 more
Mayo Clinic41 enrolled7 locationsNCT06834373